Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Johan Bjorkegren
Icahn School of Medicine at Mount Sinai, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Clinical Gene Networks
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Johan Bjorkegren (a Co-Investigator on this study) is the founder and former CEO of Clinical Gene Networks (CGN), a privately-held company which seeks to commercialize clinical gene networks underlying coronary artery disease, myocardial infarction, and stroke. Dr. Bjorkegren serves as Chairman of the Board, and owns equity in the company. Dr. Bjorkegren also receives financial compensation as a consultant for CGN.
Toward Therapeutic Manipulation of Endothelial to Mesenchymal Transition
Diseases of the cardiovascular system are the #1 cause of death in the world and among these cardiovascular deaths, most are from atherosclerosis and coronary artery disease. We have found that a process called Endothelial to Mesenchymal Transition (EndMT) plays a major role in cardiovascular disease, and in particular in atherosclerosis and the vascular response to injury. This proposal seeks to leverage several novel discoveries made by our team to define the core biologic mechanisms of EndMT in atherosclerosis and cardiovascular disease, to understand how we can manipulate EndMT to promote healing after vascular grafting procedures, and ultimately to develop novel therapeutic strategies for cardiovascular disease.
Filed on March 28, 2016.
Tell us what you know about Johan Bjorkegren's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Johan Bjorkegren”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Johan Bjorkegren | Icahn School of Medicine at Mount Sinai | Conflict of Interest | Clinical Gene Networks | $200,000 - $249,999 |
| Johan Bjorkegren | Icahn School of Medicine at Mount Sinai | Conflict of Interest | Clinical Gene Networks | $20,000 - $39,999 |
| Johan Bjorkegren | Icahn School of Medicine at Mount Sinai | Conflict of Interest | Clinical Gene Networks | $80,000 - $99,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.